CLRB

Rating neutralAI Memo

Cellectar Biosciences

As of 2026-08-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Confirmatory Phase 3 site activation and early-2027 dosing • 2026-11-23

Base target: $3 / p=50% prob

Biggest risk

The bear case is that positive early-stage data do not translate into successful randomized-study execution, approval, or commercialization. The company remains highly event-driven, with meaningful clinical, regulatory, enrollment, and financing risks; analyst revisions and consensus estimates are unavailable.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The bull case is supported by reported CLOVER-WaM results in a post-BTK-inhibitor subset: 100% clinical benefit rate, 87.5% overall response rate, 79.2% major response rate, and 16-month median duration of response. Phase 3 site activation and the planned mid-2027 NDA provide a credible regulatory path [#SEC-8K-2026-08-13].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-25

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Clinical execution, financing, and dilution sensitivity
Potential mid-2027 accelerated-approval filing
The bull case is supported by reported CLOVER-WaM results in a post-BTK-inhibitor subset: 100% clinical benefit rate, 87.5% overall response rate, 79.2% major response rate, and 16-month median duration of response.

BearKey bullets

Confirmatory Phase 3 enrollment, timing, and clinical-outcome risk.
FDA or other regulatory delays could defer or prevent the planned accelerated-approval filing.
Future financing may create dilution despite the company’s stated strengthened balance sheet.

WatchKey bullets

Confirmatory Phase 3 site activation and early-2027 dosing

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $3 (p=50%)

Target spread vs base: +100% / -52%

Scenario probabilities

Bull Target: $5 (p=20%)Base Target: $3 (p=50%)Bear Target: $1 (p=30%)

Commentary

Primary company and SEC materials are constructive on clinical progress, CLOVER-WaM data, Phase 3 preparation, and the planned mid-2027 NDA. However, the packet provides no reliable post-release price reaction, analyst target revisions, options data, short-interest data, or social coverage. With low coverage and a highly binary development path, this remains a cautious monitoring thesis rather than a high-conviction bullish call.

As of 2026-08-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Clinical execution, financing, and dilution sensitivity
Potential mid-2027 accelerated-approval filing

Scenarios

Bull Target (Scenario probability)

$5 / p=20% prob

Base Target (Scenario probability)

$3 / p=50% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-08-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-23
Confirmatory Phase 3 site activation and early-2027 dosing
Cellectar initiated site-activation activities for the confirmatory iopofosine I 131 study in relapsed/refractory Waldenström macroglobulinemia; sites are expected to open in coming months and first dosing is planned for early 2027 [#SEC-8K-2026-08-13].
Prob 70.00% • Move 35.00% • Priced-in 35.00%
EVENT2026-11-23
CLR 125 Phase 1b progress in triple-negative breast cancer
The company initiated enrollment and dosed the first patients in its CLR 125 Phase 1b trial in refractory triple-negative breast cancer [#SEC-8K-2026-08-13]. Further enrollment or early clinical data could broaden the pipeline narrative, but the program remains early stage.
Prob 45.00% • Move 25.00% • Priced-in 15.00%

Short-term Catalysts

Next few weeks

Clinical execution, financing, and dilution sensitivity
2027-08-25
The investment case remains vulnerable to trial delays, enrollment risk, regulatory setbacks, and future capital needs typical of a low-coverage development-stage biotech. The latest company update describes a strengthened balance sheet but does not eliminate long-term funding risk [#SEC-8K-2026-08-13].
Prob 40% • Move -30% • Priced-in 30%

Long-term Catalysts

Months to a year

Potential mid-2027 accelerated-approval filing
2027-08-25
Management plans to submit an iopofosine I 131 NDA in mid-2027 under the FDA Accelerated Approval Program, subject to successful confirmatory-study execution and regulatory progress [#SEC-8K-2026-08-13].
Prob 35% • Move 100% • Priced-in 20%

Risks

Confirmatory Phase 3 enrollment, timing, and clinical-outcome risk.
FDA or other regulatory delays could defer or prevent the planned accelerated-approval filing.
Future financing may create dilution despite the company’s stated strengthened balance sheet.
Low analyst coverage and loose peer comparability increase uncertainty around valuation and market expectations.
The pipeline remains concentrated around iopofosine, while CLR 125 is still an early Phase 1b program.

Peers

Symbol	Summary
TVRD	Same-sector, similarly sized biotech candidate; useful for event-volatility comparison but not a direct radiopharmaceutical operating peer.
BRNS	Same-sector, similarly sized biotechnology candidate; provides a loose small-cap biotech sentiment comparison rather than a modality match.
ACTU	Same-sector, similarly sized development-stage biotech candidate; relevant mainly for clinical and financing risk comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-25

Loading AI feed…

Symbol

Summary

TVRD

Same-sector, similarly sized biotech candidate; useful for event-volatility comparison but not a direct radiopharmaceutical operating peer.

BRNS

Same-sector, similarly sized biotechnology candidate; provides a loose small-cap biotech sentiment comparison rather than a modality match.

ACTU

Same-sector, similarly sized development-stage biotech candidate; relevant mainly for clinical and financing risk comparison.